Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neuragen Biotherapeutics (Suzhou) Co. Ltd. is currently navigating the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution effort involves 1 distinct examiner and 1 distinct art unit, which reflects a concentrated approach to its current patent filings. Such a focused profile suggests that the company's current activity is limited to a single technical inquiry within the patent office. For practitioners, the presence of 1 distinct art unit indicates that the prosecution is confined to a specific administrative group, potentially streamlining the management of the application.
The busiest examiner, PAK, MICHAEL D, is assigned 1 busiest examiner pending office action. Since the total number of pending office actions is 1, this examiner is the sole point of contact for the company's active matters. The alignment between 1 distinct examiner and the total workload indicates a streamlined prosecution path where no other examiners are currently involved. Practitioners can conclude that the 1 busiest examiner pending office action is the primary driver of the current portfolio status, requiring focused attention on this single individual's review process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.3% | +30.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924685 | METHOD FOR INDUCING GLIAL CELLS TRANSDIFFERENTIATION INTO FUNCTIONAL NEURONS, AND APPLICATION THEREOF | PAK, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17924685 | METHOD FOR INDUCING GLIAL CELLS TRANSDIFFERENTIATION INTO FUNCTIONAL NEURONS, AND APPLICATION THEREOF | PAK, MICHAEL D | 1674 | §112 | Non-Final OA | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial